Please wait a moment until all data is loaded. This message will disappear when all data is loaded.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
ankyrin repeat domain of endogenous Notch receptor L-asparagine + 2-oxoglutarate + O2
ankyrin repeat domain of endogenous Notch receptor 3-hydroxy-L-asparagine + succinate + CO2
-
hydroxylation of highly conserved asparaginyl residues within the ankyrin repeat
-
-
?
ankyrin repeat domain protein
?
-
a maximum of three ankyrin repeats enables ankyrin repeat domain proteins as a substrate
-
-
?
HIF (L-Asn803) + 2-oxoglutarate + O2
HIF (3-hydroxy-L-Asn803) + succinate + CO2
-
accepts HIF-1alpha and HIF-2-alpha as substrate, HIF mutant V802A exhibits 4fold lower substrate activity than native protein, no activity with N803A mutant
-
-
?
HIF-1alpha peptide Asp788-Leu822 (L-Asn803) + 2-oxoglutarate + O2
HIF-1alpha peptide Asp788-Leu822 (3-hydroxy-L-Asn803) + succinate + CO2
much lower activity with peptides lacking residues 819-822, 807-822, and 815-822
-
-
?
HIF-1alpha peptide Asp788-Leu822 (L-asparagine803) + 2-oxoglutarate + O2
?
-
-
-
r
peptide L-asparagine + 2-oxoglutarate + O2
peptide 3-hydroxy-L-asparagine + succinate + CO2
peptide L-aspartate + 2-oxoglutarate + O2
peptide 3-hydroxy-L-aspartate + succinate + CO2
peptide-L-aspartate + 2-oxoglutarate + O2
peptide-3-hydroxy-L-aspartate + succinate + CO2
[factor X first EGF-like domain]-L-aspartate + 2-oxoglutarate + O2
[factor X first EGF-like domain]-3-hydroxy-L-aspartate + succinate + CO2
-
-
-
?
[thioether-linked cyclic peptide hFX-CP101-119]-L-aspartate + 2-oxoglutarate + O2
[thioether-linked cyclic peptide hFX-CP101-119]-3-hydroxy-L-aspartate + succinate + CO2
the enzyme accepts substrates with a noncanonical EGFD disulfide connectivity (i.e. the Cys 1-2, 3-4, 5-6 disulfide pattern). Stable cyclic thioether analogues of the noncanonical EGFD AspH substrates are developed to avoid disulfide shuffling
-
-
?
additional information
?
-
peptide L-asparagine + 2-oxoglutarate + O2
peptide 3-hydroxy-L-asparagine + succinate + CO2
-
-
-
-
?
peptide L-asparagine + 2-oxoglutarate + O2
peptide 3-hydroxy-L-asparagine + succinate + CO2
-
-
-
?
peptide L-asparagine + 2-oxoglutarate + O2
peptide 3-hydroxy-L-asparagine + succinate + CO2
-
first epidermal growth factor-like domain of bovine protein S with an asparagine replacing the aspartic acid at position 18
-
-
?
peptide L-asparagine + 2-oxoglutarate + O2
peptide 3-hydroxy-L-asparagine + succinate + CO2
-
enzyme catalyzes the erythro-beta-hydroxylation of asparaginyl and aspartyl residues to form the 2S, 3R-product, possible role in the Notch signalling pathway
-
-
?
peptide L-asparagine + 2-oxoglutarate + O2
peptide 3-hydroxy-L-asparagine + succinate + CO2
-
hydroxylation of Asn803 in hypoxia-inducible transcription factor, converted protein is incapable in interacting with the transcripitonal coactivator p300
-
-
?
peptide L-asparagine + 2-oxoglutarate + O2
peptide 3-hydroxy-L-asparagine + succinate + CO2
hydroxylation of Asn803 in hypoxia-inducible transcription factor, converted protein is incapable in interacting with the transcripitonal coactivator p300
-
-
?
peptide L-aspartate + 2-oxoglutarate + O2
peptide 3-hydroxy-L-aspartate + succinate + CO2
-
first epidermal growth factor-like domain of bovine protein S as substrate
-
?
peptide L-aspartate + 2-oxoglutarate + O2
peptide 3-hydroxy-L-aspartate + succinate + CO2
-
hydroxylates epidermal growth factor-like domains in transformation-associated proteins
-
?
peptide-L-aspartate + 2-oxoglutarate + O2
peptide-3-hydroxy-L-aspartate + succinate + CO2
-
-
-
?
peptide-L-aspartate + 2-oxoglutarate + O2
peptide-3-hydroxy-L-aspartate + succinate + CO2
the enzyme catalyses hydroxylation of asparaginyl- and aspartyl-residues in epidermal growth factor-like domains
-
-
?
peptide-L-aspartate + 2-oxoglutarate + O2
peptide-3-hydroxy-L-aspartate + succinate + CO2
the enzyme catalyzes the post-translational hydroxylation of Asp and Asn residues in epidermal growth factor-like domains
-
-
?
peptide-L-aspartate + 2-oxoglutarate + O2
peptide-3-hydroxy-L-aspartate + succinate + CO2
the enzyme accepts epidermal growth factor-like domain (EGFD) substrates with a noncanonical (i. e., Cys 1-2, 3-4, 5-6) disulfide pattern. Synthetic thioether linked cyclic peptide, hFX-CP101-119 is used as substrate. hFX-CP101-119 is designed based on 19 EGFD1 amino acid residues of the sequence of human coagulation factor X (hFX amino acids 101-119)
-
-
?
peptide-L-aspartate + 2-oxoglutarate + O2
peptide-3-hydroxy-L-aspartate + succinate + CO2
the substrate is the synthetic thioether linked cyclic peptide hFX-CP101-119. It is designed based on 19 EGFD1 amino acid residues of the sequence of human coagulation factor X (hFX amino acids 101-119)
-
-
?
additional information
?
-
-
overexpression may be associated with malignant transformation
-
-
?
additional information
?
-
-
the enzyme hydroxylates epidermal growth factor-like domains in transformation-associated proteins
-
-
?
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
(1S,2S,4R)-3-oxalobicyclo[2.2.1]hept-5-ene-2-carboxylic acid
-
-
1-oxalocyclopropane-1-carboxylic acid
-
-
2,2-dimethyl-4-oxopentanedioic acid
-
-
2-(2-methylpropyl)-4-oxopentanedioic acid
-
-
2-(3,3-dimethylbutyl)-4-oxopentanedioic acid
-
-
2-benzyl-4-oxopentanedioic acid
-
-
2-ethyl-4-oxopentanedioic acid
-
-
2-oxalocyclopropane-1-carboxylic acid
-
-
2-oxo-3-(3-phenylpropyl)pentanedioic acid
-
-
2-oxo-3-propylpentanedioic acid
-
-
2-oxo-3-[[4-(trifluoromethoxy)phenyl]methyl]pentanedioic acid
-
-
2-oxo-4-(3-phenylpropyl)pentanedioic acid
-
-
2-oxo-4-propylpentanedioic acid
-
-
2-[(naphthalen-2-yl)methyl]-4-oxopentanedioic acid
-
-
3-((3-phenylpropyl)amino)pyridine-2,4-dicarboxylic acid
-
-
3-((4-(trifluoromethyl)benzyl)amino)pyridine-2,4-dicarboxylic acid
-
-
3-((4-chlorophenethyl)amino)pyridine-2,4-dicarboxylic acid
-
-
3-((4-methoxybenzyl)amino)pyridine-2,4-dicarboxylic acid
-
-
3-((4-phenylbutyl)amino)pyridine-2,4-dicarboxylic acid
-
-
3-((cyclohexylmethyl)amino)pyridine-2,4-dicarboxylic acid
-
-
3-(2-aminoanilino)pyridine-2,4-dicarboxylic acid
-
-
3-(2-carboxyanilino)pyridine-2,4-dicarboxylic acid
-
-
3-(2-fluoroanilino)pyridine-2,4-dicarboxylic acid
-
-
3-(2-methoxyanilino)pyridine-2,4-dicarboxylic acid
-
-
3-(2-methylanilino)pyridine-2,4-dicarboxylic acid
-
-
3-(2-nitroanilino)pyridine-2,4-dicarboxylic acid
-
-
3-(3,3-dimethylbutyl)-2-oxopentanedioic acid
-
-
3-(benzylamino)pyridine-2,4-dicarboxylic acid
-
-
3-(phenethylamino)pyridine-2,4-dicarboxylic acid
-
-
3-anilinopyridine-2,4-dicarboxylic acid
-
-
3-benzyl-2-oxopentanedioic acid
-
-
3-ethyl-2-oxopentanedioic acid
-
-
3-[(3,5-dimethylphenyl)methyl]-2-oxopentanedioic acid
-
-
3-[(4-fluorophenyl)methyl]-2-oxopentanedioic acid
-
-
3-[(4-methoxyphenyl)methyl]-2-oxopentanedioic acid
-
-
3-[2-(methylsulfanyl)anilino]pyridine-2,4-dicarboxylic acid
-
-
5-oxalothiophene-2-carboxylic acid
-
-
ankyrin repeat domain
-
may function as a natural inhibitor and provide an oxygen-dependent interface that modulates hypoxia-induced factor signaling
-
dimethyloxalylglycine
-
-
Insulin-like growth factor-1
-
stimulates peptide-aspartate beta-dioxygenase protein expression and directional motility. Ethanol reduces the stimulation without inhibition of the mRNA expression
-
pyridine-2,3-dicarboxylic acid
-
pyridine-2,4-dicarboxylic acid
-
pyridine-2,6-dicarboxylic acid
-
rac-3-((1-phenylethyl)amino)pyridine-2,4-dicarboxylic acid
-
-
rac-3-((1-phenylpropyl)amino)pyridine-2,4-dicarboxylic acid
-
-
additional information
several 2-oxoglutarate analogs inhibits enzyme activity
-
additional information
-
development of a ScFv anti-HAAH antibody for specific in vivo inhibition of the enzyme by expression of His-tagged light and heavy chain cloned from the hybridoma cells G3/F11 in Escherichia coli strain BL21(DE3)PlysS/pET-16b, partly in inclusion bodies, or of c-myc-tagged ScFv in Escherichia coli strain HB2151/pHEN1, partly cytosolic. Variable regions of the genes of the heavy chain and light chain are connected with a flexible linker using an overlap extension PCR. Nucleotide sequence analysis revealed that the anti-HAAH VH was a member of the VH V gene family and the VL gene belonged to the Vk gene family VI subgroup
-
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Abortion, Missed
[Expression of aspartyl-(asparaginyl) beta-hydroxylase in villi in patients with missed abortion]
Abortion, Spontaneous
Role of aspartyl-(asparaginyl) beta-hydroxylase in placental implantation: Relevance to early pregnancy loss.
Bile Duct Neoplasms
Detection of human aspartyl (asparaginyl) beta-hydroxylase and homeobox B7 mRNA in brush cytology specimens from patients with bile duct cancer.
Breast Neoplasms
Cytoplasmic location of factor-inhibiting hypoxia-inducible factor is associated with an enhanced hypoxic response and a shorter survival in invasive breast cancer.
Breast Neoplasms
DNA methylation analysis of the HIF-1? prolyl hydroxylase domain genes PHD1, PHD2, PHD3 and the factor inhibiting HIF gene FIH in invasive breast carcinomas.
Breast Neoplasms
The key hypoxia regulated gene CAIX is upregulated in basal-like breast tumours and is associated with resistance to chemotherapy.
Breast Neoplasms
[Expression of ASPH Gene in Invasive Breast Cancer and Its Clinical Significance in Promoter Methylation].
CADASIL
Glial Vascular Degeneration in CADASIL.
Carcinoma
Aspartyl-(asparaginyl)-beta-hydroxylase regulates hepatocellular carcinoma invasiveness.
Carcinoma
Co-targeting of multiple microRNAs on factor-inhibiting hypoxia-inducible factor (FIH) gene for the pathogenesis of head and neck carcinomas.
Carcinoma
Factor-inhibiting hypoxia-inducible factor expression in patients with high-risk locally advanced renal cell carcinoma and its relationship with tumor progression.
Carcinoma
Human aspartyl (asparaginyl) beta-hydroxylase monoclonal antibodies: potential biomarkers for pancreatic carcinoma.
Carcinoma
Prognostic value of aspartyl (asparaginyl)-beta-hydroxylase/humbug expression in non-small cell lung carcinoma.
Carcinoma
Prognostic value of humbug gene overexpression in stage II colon cancer.
Carcinoma
The aspartyl (asparaginyl) beta-hydroxylase in carcinomas.
Carcinoma, Hepatocellular
Aspartyl-(asparaginyl)-beta-hydroxylase regulates hepatocellular carcinoma invasiveness.
Carcinoma, Hepatocellular
Aspartyl-asparagyl beta hydroxylase over-expression in human hepatoma is linked to activation of insulin-like growth factor and notch signaling mechanisms.
Carcinoma, Hepatocellular
Expression of aspartyl beta-hydroxylase and its clinicopathological significance in hepatocellular carcinoma.
Carcinoma, Hepatocellular
Monoclonal antibodies against human aspartyl (asparaginyl) beta-hydroxylase developed by DNA immunization.
Carcinoma, Hepatocellular
Overexpression of aspartyl-(asparaginyl)-beta-hydroxylase in hepatocellular carcinoma is associated with worse surgical outcome.
Carcinoma, Hepatocellular
Prognostic value of humbug gene overexpression in stage II colon cancer.
Carcinoma, Hepatocellular
Prolyl hydroxylase domain protein 3 and asparaginyl hydroxylase factor inhibiting HIF-1 levels are predictive of tumoral behavior and prognosis in hepatocellular carcinoma.
Carcinoma, Renal Cell
Factor-inhibiting hypoxia-inducible factor expression in patients with high-risk locally advanced renal cell carcinoma and its relationship with tumor progression.
Carcinoma, Renal Cell
[Growth Regulation of Factor Inhibiting Hypoxia-Inducible Factor in Renal Carcinoma Cells].
Cholangiocarcinoma
Antisense oligodeoxynucleotides directed against aspartyl (asparaginyl) beta-hydroxylase suppress migration of cholangiocarcinoma cells.
Cholangiocarcinoma
Aspartate beta-hydroxylase promotes cholangiocarcinoma progression by modulating RB1 phosphorylation.
Cholangiocarcinoma
Clinicopathological correlates of aspartyl (asparaginyl) beta-hydroxylase over-expression in cholangiocarcinoma.
Cholangiocarcinoma
Prognostic value of humbug gene overexpression in stage II colon cancer.
Cholangiocarcinoma
Targeting Aspartate Beta-Hydroxylase with the Small Molecule Inhibitor MO-I-1182 Suppresses Cholangiocarcinoma Metastasis.
Fetal Alcohol Spectrum Disorders
Ethanol inhibition of aspartyl-asparaginyl-beta-hydroxylase in fetal alcohol spectrum disorder: potential link to the impairments in central nervous system neuronal migration.
Glioblastoma
The Role of Factor Inhibiting HIF (FIH-1) in Inhibiting HIF-1 Transcriptional Activity in Glioblastoma Multiforme.
Kidney Neoplasms
Factor inhibiting HIF (FIH-1) promotes renal cancer cell survival by protecting cells from HIF-1?-mediated apoptosis.
Myocardial Infarction
Double knockdown of prolyl hydroxylase and factor-inhibiting hypoxia-inducible factor with nonviral minicircle gene therapy enhances stem cell mobilization and angiogenesis after myocardial infarction.
Neoplasm Metastasis
Expression of aspartyl beta-hydroxylase and its clinicopathological significance in hepatocellular carcinoma.
Neoplasm Metastasis
Targeting Aspartate Beta-Hydroxylase with the Small Molecule Inhibitor MO-I-1182 Suppresses Cholangiocarcinoma Metastasis.
Neoplasms
A hypoxic niche regulates glioblastoma stem cells through hypoxia inducible factor 2 alpha.
Neoplasms
Antisense oligonucleotides selectively regulate aspartyl beta-hydroxylase and its truncated protein isoform in vitro but distribute poorly into A549 tumors in vivo.
Neoplasms
Aspartate beta-hydroxylase promotes cholangiocarcinoma progression by modulating RB1 phosphorylation.
Neoplasms
Aspartyl-asparagyl beta hydroxylase over-expression in human hepatoma is linked to activation of insulin-like growth factor and notch signaling mechanisms.
Neoplasms
Clinicopathological correlates of aspartyl (asparaginyl) beta-hydroxylase over-expression in cholangiocarcinoma.
Neoplasms
Detection of human aspartyl (asparaginyl) beta-hydroxylase and homeobox B7 mRNA in brush cytology specimens from patients with bile duct cancer.
Neoplasms
Expression of aspartyl beta-hydroxylase and its clinicopathological significance in hepatocellular carcinoma.
Neoplasms
Expression of HIF-2a in clear-cell renal cell carcinoma independently predicts overall survival.
Neoplasms
Factor-inhibiting hypoxia-inducible factor expression in patients with high-risk locally advanced renal cell carcinoma and its relationship with tumor progression.
Neoplasms
Investigation of FIH-1 and SOCS3 expression in KRAS mutant and wild-type patients with colorectal cancer.
Neoplasms
Isolation and characterization of human antibodies targeting human aspartyl (asparaginyl) beta-hydroxylase.
Neoplasms
Regulation of IL-1?-induced NF-?B by hydroxylases links key hypoxic and inflammatory signaling pathways.
Neoplasms
Role of the aspartyl-asparaginyl-beta-hydroxylase gene in neuroblastoma cell motility.
Neoplasms
Targeting Aspartate Beta-Hydroxylase with the Small Molecule Inhibitor MO-I-1182 Suppresses Cholangiocarcinoma Metastasis.
Neoplasms
The distribution and expression profiles of human Aspartyl/Asparaginyl beta-hydroxylase in tumor cell lines and human tissues.
Neoplasms
The key hypoxia regulated gene CAIX is upregulated in basal-like breast tumours and is associated with resistance to chemotherapy.
Neoplasms
Transcriptional activity and Sp 1/3 transcription factor binding to the P1 promoter sequences of the human AbetaH-J-J locus.
Neoplasms
[Expression of human aspartyl beta-hydroxylase and preparation of its monoclonal antibody].
Neoplasms
[Research on Relationship of HIF-1 Signaling Pathway and Postmenstrual Osteoporosis].
Neoplasms
[The distribution and expression pro-files of Aspartyl/Asparaginyl beta-hydroxylase (ASPH) in some tumorous cell lines and tissues]
Neuroblastoma
Differential growth factor regulation of aspartyl-(asparaginyl)-beta-hydroxylase family genes in SH-Sy5y human neuroblastoma cells.
Neuroblastoma
Role of the aspartyl-asparaginyl-beta-hydroxylase gene in neuroblastoma cell motility.
Squamous Cell Carcinoma of Head and Neck
Co-targeting of multiple microRNAs on factor-inhibiting hypoxia-inducible factor (FIH) gene for the pathogenesis of head and neck carcinomas.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
0.0193
(1S,2S,4R)-3-oxalobicyclo[2.2.1]hept-5-ene-2-carboxylic acid
Homo sapiens
pH 7.5, 20°C
-
0.00025
(R)-gossypol
Homo sapiens
pH 7.5, 20°C
-
0.0033
1-oxalocyclopropane-1-carboxylic acid
Homo sapiens
pH 7.5, 20°C
-
0.0003
2,2-dimethyl-4-oxopentanedioic acid
Homo sapiens
pH 7.5, 20°C
-
0.00051
2-(2-methylpropyl)-4-oxopentanedioic acid
Homo sapiens
pH 7.5, 20°C
-
0.0007
2-(3,3-dimethylbutyl)-4-oxopentanedioic acid
Homo sapiens
pH 7.5, 20°C
-
0.00043
2-benzyl-4-oxopentanedioic acid
Homo sapiens
pH 7.5, 20°C
-
0.00061
2-ethyl-4-oxopentanedioic acid
Homo sapiens
pH 7.5, 20°C
-
0.00052
2-oxalocyclopropane-1-carboxylic acid
Homo sapiens
pH 7.5, 20°C
-
0.0068
2-oxo-3-(3-phenylpropyl)pentanedioic acid
Homo sapiens
pH 7.5, 20°C
-
0.0057
2-oxo-3-propylpentanedioic acid
Homo sapiens
pH 7.5, 20°C
-
0.0063
2-oxo-3-[[4-(trifluoromethoxy)phenyl]methyl]pentanedioic acid
Homo sapiens
pH 7.5, 20°C
-
0.00025
2-oxo-4-(3-phenylpropyl)pentanedioic acid
Homo sapiens
pH 7.5, 20°C
-
0.00047
2-oxo-4-propylpentanedioic acid
Homo sapiens
pH 7.5, 20°C
-
0.00017
2-[(naphthalen-2-yl)methyl]-4-oxopentanedioic acid
Homo sapiens
pH 7.5, 20°C
-
0.0109
3-((3-phenylpropyl)amino)pyridine-2,4-dicarboxylic acid
Homo sapiens
pH 7.5, 20°C
-
0.00186
3-((4-(trifluoromethyl)benzyl)amino)pyridine-2,4-dicarboxylic acid
Homo sapiens
pH 7.5, 20°C
-
0.00367
3-((4-chlorophenethyl)amino)pyridine-2,4-dicarboxylic acid
Homo sapiens
pH 7.5, 20°C
-
0.00058
3-((4-methoxybenzyl)amino)pyridine-2,4-dicarboxylic acid
Homo sapiens
pH 7.5, 20°C
-
0.0108
3-((4-phenylbutyl)amino)pyridine-2,4-dicarboxylic acid
Homo sapiens
pH 7.5, 20°C
-
0.0131
3-((cyclohexylmethyl)amino)pyridine-2,4-dicarboxylic acid
Homo sapiens
pH 7.5, 20°C
-
0.00467
3-(2-aminoanilino)pyridine-2,4-dicarboxylic acid
Homo sapiens
pH 7.5, 20°C
-
0.0104
3-(2-carboxyanilino)pyridine-2,4-dicarboxylic acid
Homo sapiens
pH 7.5, 20°C
-
0.0221
3-(2-fluoroanilino)pyridine-2,4-dicarboxylic acid
Homo sapiens
pH 7.5, 20°C
-
0.0138
3-(2-methoxyanilino)pyridine-2,4-dicarboxylic acid
Homo sapiens
pH 7.5, 20°C
-
0.0129
3-(2-methylanilino)pyridine-2,4-dicarboxylic acid
Homo sapiens
pH 7.5, 20°C
-
0.0161
3-(2-nitroanilino)pyridine-2,4-dicarboxylic acid
Homo sapiens
pH 7.5, 20°C
-
0.0482
3-(3,3-dimethylbutyl)-2-oxopentanedioic acid
Homo sapiens
pH 7.5, 20°C
-
0.00395
3-(benzylamino)pyridine-2,4-dicarboxylic acid
Homo sapiens
pH 7.5, 20°C
-
0.00766
3-(phenethylamino)pyridine-2,4-dicarboxylic acid
Homo sapiens
pH 7.5, 20°C
-
0.0388
3-anilinopyridine-2,4-dicarboxylic acid
Homo sapiens
pH 7.5, 20°C
-
0.0016
3-benzyl-2-oxopentanedioic acid
Homo sapiens
pH 7.5, 20°C
-
0.012
3-ethyl-2-oxopentanedioic acid
Homo sapiens
pH 7.5, 20°C
-
0.0047
3-[(3,5-dimethylphenyl)methyl]-2-oxopentanedioic acid
Homo sapiens
pH 7.5, 20°C
-
0.0026
3-[(4-fluorophenyl)methyl]-2-oxopentanedioic acid
Homo sapiens
pH 7.5, 20°C
-
0.0036
3-[(4-methoxyphenyl)methyl]-2-oxopentanedioic acid
Homo sapiens
pH 7.5, 20°C
-
0.0161
3-[2-(methylsulfanyl)anilino]pyridine-2,4-dicarboxylic acid
Homo sapiens
pH 7.5, 20°C
-
0.0129
5-oxalothiophene-2-carboxylic acid
Homo sapiens
pH 7.5, 20°C
-
0.00307
AS-8351
Homo sapiens
pH 7.5, 20°C
-
0.00749
belinostat
Homo sapiens
pH 7.5, 20°C
0.00147
bleomycin A2
Homo sapiens
pH 7.5, 20°C
0.00439
ciclopirox olamine
Homo sapiens
pH 7.5, 20°C
0.00039
Co2+
Homo sapiens
pH 7.5, 20°C
0.0111
daprodustat
Homo sapiens
pH 7.5, 20°C
-
0.00208
deferasirox
Homo sapiens
pH 7.5, 20°C
-
0.00489
deferiprone
Homo sapiens
pH 7.5, 20°C
0.00316
deferoxamine mesylate
Homo sapiens
pH 7.5, 20°C
0.0163
desidustat
Homo sapiens
pH 7.5, 20°C
-
0.00012
ebselen
Homo sapiens
pH 7.5, 20°C
0.129
GSK-J1
Homo sapiens
pH 7.5, 20°C
0.00007
IOX1
Homo sapiens
pH 7.5, 20°C
0.00424
JIB-04
Homo sapiens
pH 7.5, 20°C
0.00506
L-mimosine
Homo sapiens
pH 7.5, 20°C
0.00943
midostaurin
Homo sapiens
pH 7.5, 20°C
0.0095
mithramycin A
Homo sapiens
pH 7.5, 20°C
0.00465
ML324
Homo sapiens
pH 7.5, 20°C
-
0.00506
Mn2+
Homo sapiens
pH 7.5, 20°C
0.01342
molidustat
Homo sapiens
pH 7.5, 20°C
-
0.00103
navitoclax
Homo sapiens
pH 7.5, 20°C
-
0.00017
Ni2+
Homo sapiens
pH 7.5, 20°C
0.01547
NOFD
Homo sapiens
pH 7.5, 20°C
-
0.0129
obatoclax
Homo sapiens
pH 7.5, 20°C
-
0.00014
PBIT
Homo sapiens
pH 7.5, 20°C
-
0.0132
plicamycin
Homo sapiens
pH 7.5, 20°C
-
0.00051
pyridine-2,3-dicarboxylic acid
Homo sapiens
pH 7.5, 20°C
0.00002 - 0.00003
pyridine-2,4-dicarboxylic acid
0.00548
pyridine-2,6-dicarboxylic acid
Homo sapiens
pH 7.5, 20°C
0.00028
rac-3-((1-phenylethyl)amino)pyridine-2,4-dicarboxylic acid
Homo sapiens
pH 7.5, 20°C
-
0.00122
rac-3-((1-phenylpropyl)amino)pyridine-2,4-dicarboxylic acid
Homo sapiens
pH 7.5, 20°C
-
0.0194
roxadustat
Homo sapiens
pH 7.5, 20°C
-
0.00666
TC-E 5002
Homo sapiens
pH 7.5, 20°C
-
0.00412
tubacin
Homo sapiens
pH 7.5, 20°C
0.00439
vadadustat
Homo sapiens
pH 7.5, 20°C
-
0.00338
vemurafenib
Homo sapiens
pH 7.5, 20°C
-
0.0014
venetoclax
Homo sapiens
pH 7.5, 20°C
-
0.00005
Zn2+
Homo sapiens
pH 7.5, 20°C
0.00002
pyridine-2,4-dicarboxylic acid
Homo sapiens
pH 7.5, 20°C
0.00003
pyridine-2,4-dicarboxylic acid
Homo sapiens
pH 7.5, 20°C
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Ince, N.; De la Monte, S.M.; Wands, J.R.
Overexpression of human aspartyl (asparaginyl) beta-hydroxylase is associated with malignant transformation
Cancer Res.
60
1261-1266
2000
Homo sapiens
brenda
Lavaissiere, L.; Jia, S.; Nishiyama, M.; de la Monte, S.; Stern, A.M.; Wands, J.R.; Friedman, P.A.
Overexpression of human aspartyl(asparaginyl)beta-hydroxylase in hepatocellular carcinoma and cholangiocarcinoma
J. Clin. Invest.
98
1313-1323
1996
Homo sapiens
brenda
Korioth, F.; Gieffers, C.; Frey, J.
Cloning and characterization of the human gene encoding aspartyl beta-hydroxylase
Gene
150
395-399
1994
Homo sapiens
brenda
Lancaster, D.E.; McDonough, M.A.; Schofield, C.J.
Factor inhibiting hypoxia-inducible factor (FIH) and other asparaginyl hydroxylases
Biochem. Soc. Trans.
32
943-945
2004
Homo sapiens
brenda
Linke, S.; Stojkoski, C.; Kewley, R.J.; Booker, G.W.; Whitelaw, M.L.; Peet, D.J.
Substrate requirements of the oxygen-sensing asparaginyl hydroxylase factor-inhibiting hypoxia-inducible factor
J. Biol. Chem.
279
14391-14397
2004
Homo sapiens
brenda
Koivunen, P.; Hirsilae, M.; Guenzler, V.; Kivirikko, K.I.; Myllyharju, J.
Catalytic properties of the asparaginyl hydroxylase (FIH) in the oxygen sensing pathway are distinct from those of its prolyl 4-hydroxylases
J. Biol. Chem.
279
9899-9904
2004
Homo sapiens (Q9NWT6)
brenda
Cantarini, M.C.; de la Monte, S.M.; Pang, M.; Tong, M.; DErrico, A.; Trevisani, F.; Wands, J.R.
Aspartyl-asparagyl beta hydroxylase over-expression in human hepatoma is linked to activation of insulin-like growth factor and notch signaling mechanisms
Hepatology
44
446-457
2006
Homo sapiens
brenda
Gundogan, F.; Elwood, G.; Greco, D.; Rubin, L.P.; Pinar, H.; Carlson, R.I.; Wands, J.R.; de la Monte, S.M.
Role of aspartyl-(asparaginyl) beta-hydroxylase in placental implantation: Relevance to early pregnancy loss
Hum. Pathol.
38
50-59
2007
Homo sapiens
brenda
de la Monte, S.M.; Tamaki, S.; Cantarini, M.C.; Ince, N.; Wiedmann, M.; Carter, J.J.; Lahousse, S.A.; Califano, S.; Maeda, T.; Ueno, T.; DErrico, A.; Trevisani, F.; Wands, J.R.
Aspartyl-(asparaginyl)-beta-hydroxylase regulates hepatocellular carcinoma invasiveness
J. Hepatol.
44
971-983
2006
Homo sapiens
brenda
Xian, Z.H.; Zhang, S.H.; Cong, W.M.; Yan, H.X.; Wang, K.; Wu, M.C.
Expression of aspartyl beta-hydroxylase and its clinicopathological significance in hepatocellular carcinoma
Mod. Pathol.
19
280-286
2006
Homo sapiens
brenda
Cockman, M.E.; Lancaster, D.E.; Stolze, I.P.; Hewitson, K.S.; McDonough, M.A.; Coleman, M.L.; Coles, C.H.; Yu, X.; Hay, R.T.; Ley, S.C.; Pugh, C.W.; Oldham, N.J.; Masson, N.; Schofield, C.J.; Ratcliffe, P.J.
Posttranslational hydroxylation of ankyrin repeats in IkB proteins by the hypoxia-inducible factor (HIF) asparaginyl hydroxylase, factor inhibiting HIF (FIH)
Proc. Natl. Acad. Sci. USA
103
14767-14772
2006
Homo sapiens
brenda
Carter, J.J.; Tong, M.; Silbermann, E.; Lahousse, S.A.; Ding, F.F.; Longato, L.; Roper, N.; Wands, J.R.; de la Monte, S.M.
Ethanol impaired neuronal migration is associated with reduced aspartyl-asparaginyl-beta-hydroxylase expression
Acta Neuropathol.
116
303-315
2008
Homo sapiens
brenda
Yeung, Y.A.; Finney, A.H.; Koyrakh, I.A.; Lebowitz, M.S.; Ghanbari, H.A.; Wands, J.R.; Wittrup, K.D.
Isolation and characterization of human antibodies targeting human aspartyl (asparaginyl) beta-hydroxylase
Hum. Antibodies
16
163-176
2007
Homo sapiens
brenda
Coleman, M.L.; McDonough, M.A.; Hewitson, K.S.; Coles, C.; Mecinovic, J.; Edelmann, M.; Cook, K.M.; Cockman, M.E.; Lancaster, D.E.; Kessler, B.M.; Oldham, N.J.; Ratcliffe, P.J.; Schofield, C.J.
Asparaginyl hydroxylation of the Notch ankyrin repeat domain by factor inhibiting hypoxia-inducible factor
J. Biol. Chem.
282
24027-24038
2007
Homo sapiens, Mus musculus
brenda
Luu, M.; Sabo, E.; de la Monte, S.M.; Greaves, W.; Wang, J.; Tavares, R.; Simao, L.; Wands, J.R.; Resnick, M.B.; Wang, L.
Prognostic value of aspartyl (asparaginyl)-beta-hydroxylase/humbug expression in non-small cell lung carcinoma
Hum. Pathol.
40
639-644
2009
Homo sapiens
brenda
Xue, T.; Xue, X.P.; Huang, Q.S.; Wei, L.; Sun, K.; Xue, T.
Monoclonal antibodies against human aspartyl (asparaginyl) beta-hydroxylase developed by DNA immunization
Hybridoma
28
251-257
2009
Homo sapiens
brenda
Hardy, A.P.; Prokes, I.; Kelly, L.; Campbell, I.D.; Schofield, C.J.
Asparaginyl beta-hydroxylation of proteins containing ankyrin repeat domains influences their stability and function
J. Mol. Biol.
392
994-1006
2009
Homo sapiens
brenda
Yang, H.; Wang, H.; Xue, T.; Xue, X.P.; Huyan, T.; Wang, W.; Song, K.
Single-chain variable fragment antibody against human aspartyl/asparaginyl beta-hydroxylase expressed in recombinant Escherichia coli
Hybridoma
30
69-79
2011
Homo sapiens
brenda
Lyu, F.; Xue, Q.; Gao, S.
Research progress of aspartyl-(asparaginyl) beta-hydroxylase in tumors
Cancer Res. Clinic
27
280-282
2015
Homo sapiens (Q12797)
-
brenda
Yang, H.; Li, J.; Tang, R.; Li, J.; Liu, Y.; Ye, L.; Shao, D.; Jin, M.; Huang, Q.; Shi, J.
The aspartyl (asparaginyl) beta-hydroxylase in carcinomas
Front. Biosci.
20
902-909
2015
Homo sapiens (Q12797), Homo sapiens
brenda
Iwagami, Y.; Huang, C.K.; Olsen, M.J.; Thomas, J.M.; Jang, G.; Kim, M.; Lin, Q.; Carlson, R.I.; Wagner, C.E.; Dong, X.; Wands, J.R.
Aspartate beta-hydroxylase modulates cellular senescence through glycogen synthase kinase 3beta in hepatocellular carcinoma
Hepatology
63
1213-1226
2016
Homo sapiens (Q12797)
brenda
Huyan, T.; Li, Q.; Ye, L.J.; Yang, H.; Xue, X.P.; Zhang, M.J.; Huang, Q.S.; Yin, D.C.; Shang, P.
Inhibition of human natural killer cell functional activity by human aspartyl alpha-hydroxylase
Int. Immunopharmacol.
23
452-459
2014
Homo sapiens (Q12797)
brenda
Borgas, D.L.; Gao, J.S.; Tong, M.; Roper, N.; de la Monte, S.M.
Regulation of aspartyl-(asparaginyl)-?-hydroxylase protein expression and function by phosphorylation in hepatocellular carcinoma cells
J. Nat. Sci.
1
e84
2015
Homo sapiens (Q12797)
brenda
Tang, C.; Hou, Y.; Wang, H.; Wang, K.; Xiang, H.; Wan, X.; Xia, Y.; Li, J.; Wei, W.; Xu, S.; Lei, Z.; Pawlik, T.M.; Wang, H.; Wu, M.; Shen, F.
Aspartate beta-hydroxylase disrupts mitochondrial DNA stability and function in hepatocellular carcinoma
Oncogenesis
6
e362
2017
Homo sapiens (Q12797)
brenda
Dong, X.; Lin, Q.; Aihara, A.; Li, Y.; Huang, C.K.; Chung, W.; Tang, Q.; Chen, X.; Carlson, R.; Nadolny, C.; Gabriel, G.; Olsen, M.; Wands, J.R.
Aspartate beta-hydroxylase expression promotes a malignant pancreatic cellular phenotype
Oncotarget
6
1231-1248
2015
Homo sapiens (Q12797)
brenda
Ma, M.; Hua, S.; Li, G.; Wang, S.; Cheng, X.; He, S.; Wu, P.; Chen, X.
Prolyl hydroxylase domain protein 3 and asparaginyl hydroxylase factor inhibiting HIF-1 levels are predictive of tumoral behavior and prognosis in hepatocellular carcinoma
Oncotarget
8
12983-13002
2017
Homo sapiens (Q9NWT6), Homo sapiens
brenda
Tomimaru, Y.; Mishra, S.; Safran, H.; Charpentier, K.P.; Martin, W.; De Groot, A.S.; Gregory, S.H.; Wands, J.R.
Aspartate-beta-hydroxylase induces epitope-specific T cell responses in hepatocellular carcinoma
Vaccine
33
1256-1266
2015
Homo sapiens (Q12797)
brenda
Brewitz, L.; Tumber, A.; Zhang, X.; Schofield, C.J.
Small-molecule active pharmaceutical ingredients of approved cancer therapeutics inhibit human aspartate/asparagine-beta-hydroxylase
Bioorg. Med. Chem.
28
115675
2020
Homo sapiens (Q12797)
brenda
Barboro, P.; Benelli, R.; Tosetti, F.; Costa, D.; Capaia, M.; Astigiano, S.; Vene, R.; Poggi, A.; Ferrari, N.
Aspartate beta-hydroxylase targeting in castration-resistant prostate cancer modulates the NOTCH/HIF1alpha/GSK3beta crosstalk
Carcinogenesis
41
1246-1252
2020
Homo sapiens
brenda
Brewitz, L.; Nakashima, Y.; Schofield, C.J.
Synthesis of 2-oxoglutarate derivatives and their evaluation as cosubstrates and inhibitors of human aspartate/asparagine-beta-hydroxylase
Chem. Sci.
12
1327-1342
2020
Homo sapiens (Q12797)
brenda
Brewitz, L.; Tumber, A.; Thalhammer, A.; Salah, E.; Christensen, K.E.; Schofield, C.J.
Synthesis of novel pyridine-carboxylates as small-molecule inhibitors of human aspartate/asparagine-beta-hydroxylase
ChemMedChem
15
1139-1149
2020
Homo sapiens (Q12797)
brenda
Brewitz, L.; Tumber, A.; Schofield, C.J.
Kinetic parameters of human aspartate/asparagine-beta-hydroxylase suggest that it has a possible function in oxygen sensing
J. Biol. Chem.
295
7826-7838
2020
Homo sapiens (Q12797)
brenda
Zhou, Y.; Liu, F.; Li, C.; Shi, G.; Xu, X.; Luo, X.; Zhang, Y.; Fu, J.; Zeng, A.; Chen, L.
Construction and characterization of adenovirus vectors encoding aspartate-beta-hydroxylase to preliminary application in immunotherapy of hepatocellular carcinoma
J. Immunol. Res.
2018
9832467
2018
Homo sapiens (Q12797)
brenda
Zhang, Y.; Gao, Y.; Li, Y.; Zhang, X.; Xie, H.
Characterization of the relationship between the expression of aspartate beta-hydroxylase and the pathological characteristics of breast cancer
Med. Sci. Monit.
26
e926752
2020
Homo sapiens (Q12797)
brenda
Greve, J.M.; Pinkham, A.M.; Thompson, Z.; Cowan, J.A.
Active site characterization and activity of the human aspartyl (asparaginyl) beta-hydroxylase
Metallomics
13
mfab056
2021
Homo sapiens (Q12797), Homo sapiens
brenda
Pfeffer, I.; Brewitz, L.; Krojer, T.; Jensen, S.A.; Kochan, G.T.; Kershaw, N.J.; Hewitson, K.S.; McNeill, L.A.; Kramer, H.; Muenzel, M.; Hopkinson, R.J.; Oppermann, U.; Handford, P.A.; McDonough, M.A.; Schofield, C.J.
Aspartate/asparagine-beta-hydroxylase crystal structures reveal an unexpected epidermal growth factor-like domain substrate disulfide pattern
Nat. Commun.
10
4910
2019
Homo sapiens (Q12797)
brenda
Brewitz, L.; Tumber, A.; Pfeffer, I.; McDonough, M.A.; Schofield, C.J.
Aspartate/asparagine-beta-hydroxylase a high-throughput mass spectrometric assay for discovery of small molecule inhibitors
Sci. Rep.
10
8650
2020
Homo sapiens (Q12797)
brenda